• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers.提高丁丙诺啡/纳洛酮治疗阿片类药物使用障碍的保留率的策略:来自处方者的问题和建议的定性研究。
Addict Sci Clin Pract. 2024 Nov 21;19(1):85. doi: 10.1186/s13722-024-00516-z.
2
Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?在医疗实践中开具丁丙诺啡治疗阿片类药物使用障碍:基于诊室的门诊治疗能否解决美国的阿片类药物危机?
Addiction. 2019 Nov;114(11):1992-1999. doi: 10.1111/add.14733. Epub 2019 Jul 25.
3
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.在美国商业保险人群中,接受阿片类药物使用障碍治疗的个体中,可注射纳曲酮、口服纳曲酮和丁丙诺啡的使用和停药情况。
J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3.
4
Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.在初级保健环境中,护士从业者开具丁丙诺啡治疗阿片类药物使用障碍的障碍和促进因素。
J Am Assoc Nurse Pract. 2023 Feb 1;35(2):112-121. doi: 10.1097/JXX.0000000000000811.
5
Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients' Perceptions and Attitudes.接受丁丙诺啡/纳洛酮治疗阿片类药物使用障碍的患者的治疗体验:一项对患者感知和态度的定性研究。
Subst Use Misuse. 2023;58(4):512-519. doi: 10.1080/10826084.2023.2177111. Epub 2023 Feb 10.
6
Impact of an Education Module on the Knowledge and Attitudes of EM Physicians Towards Prescribing Buprenorphine/Naloxone for Opioid Use Disorder.教育模块对急诊医师开具丁丙诺啡/纳洛酮治疗阿片类药物使用障碍知识和态度的影响。
J Opioid Manag. 2024 Jul-Aug;20(4):B13. doi: 10.5055/bupe.24.rpj.1095.
7
Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.评估急诊科用于治疗阿片类药物使用障碍的药物:2020 年国家医院门诊医疗调查的横断面分析。
Am J Emerg Med. 2024 Aug;82:52-56. doi: 10.1016/j.ajem.2024.05.015. Epub 2024 May 20.
8
Group medication management for buprenorphine/naloxone in opioid-dependent veterans.针对阿片类药物依赖退伍军人的丁丙诺啡/纳洛酮集体药物管理
J Addict Med. 2014 Nov-Dec;8(6):415-20. doi: 10.1097/ADM.0000000000000071.
9
Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.评估关于阿片类药物使用障碍和纳洛酮药物在 Twitter 上的认知。
J Addict Dis. 2021 Jan-Mar;39(1):37-45. doi: 10.1080/10550887.2020.1811456. Epub 2020 Aug 24.
10
Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.缓释注射剂与舌下含服丁丙诺啡治疗芬太尼使用相关的阿片类药物使用障碍:一项随机临床试验的事后分析。
JAMA Netw Open. 2024 Jun 3;7(6):e2417377. doi: 10.1001/jamanetworkopen.2024.17377.

引用本文的文献

1
Effectiveness of Washington State's hub and spoke model to improve opioid use disorder outcomes.华盛顿州枢纽辐射模式改善阿片类药物使用障碍治疗效果的有效性。
Health Aff Sch. 2025 Aug 7;3(8):qxaf157. doi: 10.1093/haschl/qxaf157. eCollection 2025 Aug.

本文引用的文献

1
Naloxone distribution programs in the emergency department: A scoping review of the literature.急诊科纳洛酮分发项目:文献综述
J Am Coll Emerg Physicians Open. 2024 May 8;5(3):e13180. doi: 10.1002/emp2.13180. eCollection 2024 Jun.
2
Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients' Perceptions and Attitudes.接受丁丙诺啡/纳洛酮治疗阿片类药物使用障碍的患者的治疗体验:一项对患者感知和态度的定性研究。
Subst Use Misuse. 2023;58(4):512-519. doi: 10.1080/10826084.2023.2177111. Epub 2023 Feb 10.
3
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.医疗保险受益人的远程医疗服务的接受情况、阿片类药物使用障碍药物的获得和保留情况,以及在 COVID-19 大流行之前和期间的药物治疗过量情况。
JAMA Psychiatry. 2022 Oct 1;79(10):981-992. doi: 10.1001/jamapsychiatry.2022.2284.
4
Differences in buprenorphine treatment quality across physician provider specialties.不同医生专业提供的丁丙诺啡治疗质量存在差异。
Drug Alcohol Depend. 2022 Aug 1;237:109510. doi: 10.1016/j.drugalcdep.2022.109510. Epub 2022 May 23.
5
A mixed methods study of provider factors in buprenorphine treatment retention.一项关于丁丙诺啡治疗保留中提供者因素的混合方法研究。
Int J Drug Policy. 2022 Jul;105:103715. doi: 10.1016/j.drugpo.2022.103715. Epub 2022 May 6.
6
Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review.使用丁丙诺啡的阿片类物质使用障碍患者远程医疗解决方案的应用:一项范围综述
Telemed J E Health. 2022 Jun;28(6):761-767. doi: 10.1089/tmj.2021.0308. Epub 2021 Oct 29.
7
Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.丁丙诺啡/纳洛酮治疗阿片类物质使用障碍患者停药模式:对马萨诸塞州商业保险人群的一项研究。
J Subst Abuse Treat. 2021 Dec;131:108416. doi: 10.1016/j.jsat.2021.108416. Epub 2021 Apr 20.
8
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.描述一个具有全国代表性的美国商业保险队列中,延长释放丁丙诺啡的起始使用、持续使用和停止使用情况。
Drug Alcohol Depend. 2021 Aug 1;225:108764. doi: 10.1016/j.drugalcdep.2021.108764. Epub 2021 May 21.
9
Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.保险患者新开始使用丁丙诺啡/纳洛酮治疗阿片类药物使用障碍的治疗持久性。
Ann Pharmacother. 2018 May;52(5):405-414. doi: 10.1177/1060028017751913. Epub 2018 Jan 5.
10
Random or predictable?: Adoption patterns of chronic care management practices in physician organizations.随机还是可预测?:医疗机构中慢性病管理实践的采用模式。
Implement Sci. 2017 Aug 24;12(1):106. doi: 10.1186/s13012-017-0639-z.

提高丁丙诺啡/纳洛酮治疗阿片类药物使用障碍的保留率的策略:来自处方者的问题和建议的定性研究。

Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers.

机构信息

Center for Health Policy and Healthcare Research, Northeastern University, Boston, MA, USA.

Bouve College of Health Sciences, Northeastern University, Boston, MA, USA.

出版信息

Addict Sci Clin Pract. 2024 Nov 21;19(1):85. doi: 10.1186/s13722-024-00516-z.

DOI:10.1186/s13722-024-00516-z
PMID:39574199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11580496/
Abstract

BACKGROUND

Opioid use disorder (OUD) remains a significant public health issue as the number of opioid-related overdose deaths continues to reach new highs each year. Buprenorphine/Naloxone is a medication that has been shown to be highly effective for the treatment of OUD. However, the clinical management of patients on this medication is challenging as many patients discontinue treatment prematurely. We conducted a qualitative study focusing on experienced prescribers of buprenorphine to learn about what they believe are key challenges in prescribing this medication to patients with OUD and related strategies for improving treatment outcomes.

METHODS

We conducted two rounds of interviews with 12 prescribers who were either trained as a primary care physician, nurse practitioner, or physician assistant. These prescribers were recruited from an academically-based treatment program, a community health center, and a commercial substance use disorder treatment facility. Interview data were coded and analyzed in accordance with a grounded theory approach.

RESULTS

Key findings and related recommendations emerged for patient monitoring, integration of behavioral health with prescribing, patient volume requirements, and use of telehealth.

CONCLUSION

The interviews generated a number of recommendations for improving patient outcomes from buprenorphine treatment. Some of these recommendations can be implemented quite readily whereas others entail more substantial resources and time commitments.

摘要

背景

阿片类药物使用障碍(OUD)仍然是一个重大的公共卫生问题,因为每年与阿片类药物相关的过量死亡人数持续达到新高。丁丙诺啡/纳洛酮是一种已被证明对治疗 OUD 非常有效的药物。然而,由于许多患者过早停止治疗,因此对接受这种药物治疗的患者进行临床管理具有挑战性。我们进行了一项定性研究,重点关注丁丙诺啡的经验丰富的处方医生,以了解他们认为在为 OUD 患者开这种药物方面存在哪些关键挑战,以及改善治疗效果的相关策略。

方法

我们对 12 名接受过初级保健医生、护士从业者或医师助理培训的处方医生进行了两轮访谈。这些处方医生是从一个基于学术的治疗项目、一个社区卫生中心和一个商业物质使用障碍治疗机构招募的。根据扎根理论方法对访谈数据进行编码和分析。

结果

在患者监测、行为健康与处方整合、患者数量要求和使用远程医疗方面出现了关键发现和相关建议。

结论

访谈提出了许多关于改善丁丙诺啡治疗患者结局的建议。其中一些建议可以很快实施,而其他建议则需要更多的资源和时间投入。